On Monday, RBC analysts highlighted potential risks for Galderma stock due to newly imposed 25% tariffs on imports from Canada by the United States. Galderma, which has previously outlined its ...

RBC has cut its 2025-end S&P500 target to 6,200 and its bear-case target to 5,550 from 5,775. The firm notes deteriorating Investor, Consumer, and Small Business sentiment. Published first on ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...

However, RBC notes that Centrica will likely require a highly controlled execution risk to move forward with such a venture. Beyond nuclear, Centrica has flagged various investment opportunities ...